Andrew Humberstone

1.9k total citations
31 papers, 1.5k citations indexed

About

Andrew Humberstone is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Andrew Humberstone has authored 31 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Reproductive Medicine, 9 papers in Obstetrics and Gynecology and 8 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Andrew Humberstone's work include Endometriosis Research and Treatment (9 papers), Uterine Myomas and Treatments (8 papers) and Ovarian function and disorders (4 papers). Andrew Humberstone is often cited by papers focused on Endometriosis Research and Treatment (9 papers), Uterine Myomas and Treatments (8 papers) and Ovarian function and disorders (4 papers). Andrew Humberstone collaborates with scholars based in Australia, United States and Belgium. Andrew Humberstone's co-authors include William N. Charman, Christopher J. H. Porter, Glenn A. Edwards, Shui‐Mei Khoo, Susan A. Charman, Secondo Sonza, Tim Spelman, G.R. Lewis, Jeremy Ra Paull and Clare F. Price and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Andrew Humberstone

27 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Humberstone Australia	13	767	293	218	201	170	31	1.5k
Shaimaa M. Badr-Eldin Saudi Arabia	26	1.0k 1.3×	489 1.7×	111 0.5×	82 0.4×	119 0.7×	75	2.3k
Don K. Walker United Kingdom	22	135 0.2×	631 2.2×	309 1.4×	87 0.4×	385 2.3×	40	2.2k
William R. Ravis United States	20	310 0.4×	271 0.9×	156 0.7×	67 0.3×	101 0.6×	116	1.4k
Robert G. Strickley United States	16	780 1.0×	571 1.9×	134 0.6×	30 0.1×	142 0.8×	22	2.1k
Sompol Prakongpan Thailand	21	389 0.5×	152 0.5×	91 0.4×	61 0.3×	35 0.2×	30	900
Robert M. Fielding United States	21	150 0.2×	342 1.2×	183 0.8×	164 0.8×	87 0.5×	35	1.6k
Mahesh Patel India	27	330 0.4×	628 2.1×	84 0.4×	28 0.1×	55 0.3×	100	2.2k
Richard J. Prankerd Australia	21	237 0.3×	392 1.3×	119 0.5×	174 0.9×	84 0.5×	67	1.3k
Eric Galia Germany	7	843 1.1×	135 0.5×	179 0.8×	38 0.2×	90 0.5×	10	1.1k
Shui‐Mei Khoo Australia	11	655 0.9×	396 1.4×	150 0.7×	30 0.1×	89 0.5×	11	1.3k

Countries citing papers authored by Andrew Humberstone

Since Specialization

Citations

This map shows the geographic impact of Andrew Humberstone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Humberstone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Humberstone more than expected).

Fields of papers citing papers by Andrew Humberstone

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Humberstone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Humberstone. The network helps show where Andrew Humberstone may publish in the future.

Co-authorship network of co-authors of Andrew Humberstone

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Humberstone. A scholar is included among the top collaborators of Andrew Humberstone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Humberstone. Andrew Humberstone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Donnez, Jacques, Hugh S. Taylor, Elizabeth A. Stewart, et al.. (2022). Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. The Lancet. 400(10356). 896–907. 39 indexed citations

Stewart, Elizabeth A., Erica E. Marsh, Jacques Donnez, et al.. (2022). Effect of the Oral GnRH Antagonist Linzagolix on Uterine Fibroid-Related Severe Anemia [A105]. Obstetrics and Gynecology. 139(1). 31S–31S.

Donnez, Jacques, Olivier Donnez, Elke Bestel, et al.. (2021). Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New ’Hit Hard First and then Maintain’ Regimen of Administration. Journal of Clinical Medicine. 10(24). 5794–5794. 16 indexed citations

Donnez, Jacques, Olivier Donnez, Elke Bestel, et al.. (2021). Treatment of symptomatic uterine adenomyosis with linzagolix, an oral gonadotrophin-releasing hormone antagonist: a pilot study. Reproductive BioMedicine Online. 44(1). 200–203. 12 indexed citations

Taylor, Hugh S., Jacques Donnez, Felice Petraglia, et al.. (2021). O-135 Long term secondary efficacy of linzagolix for heavy menstrual bleeding (HMB) due to uterine fibroids (UF): 52-week results from two placebo-controlled, randomized, phase 3 trials. Human Reproduction. 36(Supplement_1). 1 indexed citations

Griesinger, Georg, Jacques Donnez, Andrew Humberstone, et al.. (2020). THE EFFECT OF THE ORAL OXYTOCIN ANTAGONIST, NOLASIBAN, ON PREGNANCY RATES IN WOMEN UNDERGOING EMBRYO TRANSFER FOLLOWING IVF. Fertility and Sterility. 114(3). e303–e303. 1 indexed citations

Stewart, Elizabeth A., Hugh S. Taylor, Robert N. Taylor, et al.. (2020). EFFICACY AND SAFETY OF LINZAGOLIX (LGX) FOR THE TREATMENT OF HEAVY MENSTRUAL BLEEDING (HMB) DUE TO UTERINE FIBROIDS (UF): RESULTS FROM TWO PHASE 3 RANDOMIZED CLINICAL TRIALS. Fertility and Sterility. 114(3). e527–e527. 10 indexed citations

Taylor, Robert N., Elke Bestel, Jean‐Pierre Gotteland, et al.. (2019). Long term treatment of endometriosis associated pain (EAP) with linzagolix: efficacy and safety after 12 months of treatment. Fertility and Sterility. 112(3). e323–e323. 8 indexed citations

Humberstone, Andrew, et al.. (2019). Babies born following administration of nolasiban before embryo transfer (ET) after IVF: neonatal and infant development outcomes from a double-blind, placebo-controlled, clinical trial. Fertility and Sterility. 112(3). e7–e8.

10.

Davis, Susan R., Allan M. Evans, & Andrew Humberstone. (2014). Application Site Affects the Pharmacokinetics of Topical Testosterone Applied to the Axilla Compared With the Inner Arm. Clinical Therapeutics. 36(10). 1395–1401. 2 indexed citations

11.

Zaloumis, Sophie, Andrew Humberstone, Susan A. Charman, et al.. (2012). Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development. Malaria Journal. 11(1). 303–303. 37 indexed citations

12.

Price, Clare F., David Tyssen, Secondo Sonza, et al.. (2011). SPL7013 Gel (VivaGel®) Retains Potent HIV-1 and HSV-2 Inhibitory Activity following Vaginal Administration in Humans. PLoS ONE. 6(9). e24095–e24095. 136 indexed citations

13.

McCarthy, James, Silvana Sekuloski, Paul Griffin, et al.. (2011). A Pilot Randomised Trial of Induced Blood-Stage Plasmodium falciparum Infections in Healthy Volunteers for Testing Efficacy of New Antimalarial Drugs. PLoS ONE. 6(8). e21914–e21914. 115 indexed citations

14.

Fraser, Ian S., Edith Weisberg, Narender Kumar, et al.. (2007). An initial pharmacokinetic study with a Metered Dose Transdermal System® for delivery of the progestogen Nestorone® as a possible future contraceptive. Contraception. 76(6). 432–438. 32 indexed citations

15.

Humberstone, Andrew, Alan F. Cowman, John Horton, & William N. Charman. (1998). Effect of Altered Serum Lipid Concentrations on the IC50 of Halofantrine against Plasmodium Falciparum. Journal of Pharmaceutical Sciences. 87(2). 256–258. 21 indexed citations

16.

Humberstone, Andrew, Christopher J. H. Porter, Glenn A. Edwards, & William N. Charman. (1998). Association of Halofantrine with Postprandially Derived Plasma Lipoproteins Decreases Its Clearance Relative To Administration in the Fasted State. Journal of Pharmaceutical Sciences. 87(8). 936–942. 53 indexed citations

17.

Porter, Christopher J. H., Susan A. Charman, Andrew Humberstone, & William N. Charman. (1996). Lymphatic Transport of Halofantrine in the Conscious Rat When Administered as Either the Free Base or the Hydrochloride Salt: Effect of Lipid Class and Lipid Vehicle Dispersion. Journal of Pharmaceutical Sciences. 85(4). 357–361. 58 indexed citations

18.

Humberstone, Andrew, Christopher J. H. Porter, & William N. Charman. (1996). A physicochemical Basis for the Effect of Food on the Absolute Oral Bioavailability of Halofantrine. Journal of Pharmaceutical Sciences. 85(5). 525–529. 109 indexed citations

19.

Humberstone, Andrew, Graeme Currie, Christopher J. H. Porter, M.J. Scanlon, & William N. Charman. (1995). A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkaline conditions. Journal of Pharmaceutical and Biomedical Analysis. 13(3). 265–272. 45 indexed citations

20.

Charman, William N., Andrew Humberstone, & Susan A. Charman. (1992). Analysis of Pilocarpine and Its Degradation Products by Micellar Electrokinetic Capillary Chromatography. Pharmaceutical Research. 9(9). 1219–1223. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact